Drug safety in pregnancy - monitoring congenital anomalies

Journal of Nursing Management

Volumn 19, Issue 3, 2011, Pages 305-310

  Morgan, Margery ^a   De Jong Van Den Berg, Lolkje T W ^b   Jordan, Sue ^c  

^a SINGLETON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Congenital anomalies; Nurses and midwives; Research methods

Indexed keywords

TERATOGENIC AGENT;

ARTICLE; CONFUSION; COOPERATION; DRUG TOXICITY; EUROPE; FEMALE; HUMAN; METHODOLOGY; MIDWIFE; NURSING; NURSING RESEARCH; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS; REGISTER; RISK ASSESSMENT; STATISTICS;

CONFUSION; COOPERATIVE BEHAVIOR; DRUG TOXICITY; EUROPE; FEMALE; HUMANS; MIDWIFERY; NURSING RESEARCH; NURSING, SUPERVISORY; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS; REGISTRIES; RISK ASSESSMENT; TERATOGENS;

EID: 79955001351     PISSN: 09660429     EISSN: 1365263X     Source Type: Journal    
DOI: 10.1111/j.1365-2834.2011.01250.x     Document Type: Article

References (15)

1. Aronson J.K. (2006) Meyler's Side Effects of Drugs: the International Encyclopedia of Adverse Drug Reactions and Interactions, Elsevier, New York, NY.
2. British National Formulary (2010) British National Formulary No. 60. British Medical Association and the Pharmaceutical Society of Great Britain, London.
3. Burns L., Mattick R.P. & Cooke M. (2006) The use of record linkage to examine illicit drug use in pregnancy. Addiction 101 (6), 873-882.
4. CARIS (2010) CARIS, the congenital anomaly register and information service for wales. Available at:, accessed 21 January 2011].
5. Chow K.M. & Lam C.M. (2004) Angiotensin II receptor antagonist in pregnancy. Journal of Perinatology 24, 56-57.
6. Cooper W.O., Hernandez-Diaz S., Arbogast P.G. et al. (2006) Major congenital anomalies after first trimester exposure to ACE-inhibitors. New England Journal of Medicine 354, 2443-2451.
7. Dolk H., Jentink J., Loane M.A. et al. (2008) Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 71, 714-722.
8. Jentink J., Loane M.A., Dolk H. et al. (2010a) Valproic acid monotherapy in pregnancy and major congenital malformations. New England Journal of Medicine 362, 2185-2193.
9. Jentink J., Dolk H., Loane M.A. et al. (2010b) Intrauterine carbamazepine exposure and specific congenital malformations: systematic review and case-control study. BMJ 341, c6581. doi:.
10. Jordan S. (2010) Pharmacology for Midwives: The Evidence Base for Safe Practice, 2nd edn. Palgrave Macmillan, Basingstoke.
11. MHRA (2010) Medicines and healthcare products regulatory agency. Available at:, accessed 25 January 2011.
12. Mitchell A.A. (2003) Systematic identification of drugs that cause birth defects - a new opportunity. New England Journal of Medicine 349 (26), 2556-2559.
13. NICE (2008) National Institute for Health and Clinical Excellence, Diabetes in Pregnancy clinical guideline 63, published by NICE, London, Available at:, accessed 30th March 2011.
14. Palmer S.R., Dunstan F.D., Fielder H., Fone D.L., Higgs G. & Senior M.L. (2005) Risk of congenital anomalies after the opening of landfill sites. Environmental Health Perspectives 113 (10), 1362-1365.
15. Rasmussen S.A. & Frías J.L. (2008) Non-genetic risk factors for gastroschisis. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 148C (3m), 199-212.